MA41873B2 - Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof - Google Patents

Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof

Info

Publication number
MA41873B2
MA41873B2 MA41873A MA41873A MA41873B2 MA 41873 B2 MA41873 B2 MA 41873B2 MA 41873 A MA41873 A MA 41873A MA 41873 A MA41873 A MA 41873A MA 41873 B2 MA41873 B2 MA 41873B2
Authority
MA
Morocco
Prior art keywords
bind
antibodies
binding molecules
bispecific antigen
present
Prior art date
Application number
MA41873A
Other languages
French (fr)
Other versions
MA41873A1 (en
Inventor
Nicholas Papadopoulos
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2013/060511 external-priority patent/WO2014047231A1/en
Publication of MA41873A1 publication Critical patent/MA41873A1/en
Publication of MA41873B2 publication Critical patent/MA41873B2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui se lient à cd3 et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps de l'invention se lient à cd3 humain à affinité élevée et induisent la prolifération de lymphocytes t humains. L'invention comprend des anticorps qui se lient à cd3 et induisent la mort à médiation par des lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bisThe present invention relates to antibodies that bind to cd3 and methods of using them. In some embodiments, the antibodies of the invention bind to high affinity human cd3 and induce proliferation of human t cells. The invention includes antibodies that bind to cd3 and induce t-cell mediated death of tumor cells. Embodiments of the present invention relate to bis antigen-binding molecules

MA41873A 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof MA41873B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261704029P 2012-09-21 2012-09-21
PCT/US2013/060511 WO2014047231A1 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Publications (2)

Publication Number Publication Date
MA41873A1 MA41873A1 (en) 2018-07-31
MA41873B2 true MA41873B2 (en) 2022-04-29

Family

ID=59745478

Family Applications (2)

Application Number Title Priority Date Filing Date
MA37998A MA37998B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses
MA41873A MA41873B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA37998A MA37998B2 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind to cd3 and cd20, and their uses

Country Status (1)

Country Link
MA (2) MA37998B2 (en)

Also Published As

Publication number Publication date
MA41873A1 (en) 2018-07-31
MA37998B2 (en) 2020-07-29
MA37998A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
MA49043B1 (en) STABLE ANTIBODY FORMULATION
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
TN2019000159A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
MA34749B1 (en) LOW AFFINITY HEMATO-ENCEPHALIC BARRIER ANTI-RECEPTOR ANTIBODIES AND USES THEREOF
MA38632A1 (en) Anti-transferrin receptor antibody and methods of use
BR112018014760A2 (en) anti-ror1 antibodies, bispecific antibodies to ror1 x cd3 and methods of use
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
MA34927B1 (en) ANTI-ACE ANTIBODIES
MA39061A1 (en) Aplnr modulators and their uses
UA106070C2 (en) Antibody that specifically binds to egfr and her3
MA35711B1 (en) Anti-alphabetatcr antibodies
MA35740B1 (en) Compositions and methods for antibodies targeting the factor p
PH12020500667A1 (en) Multispecific antibodies and use thereof
CL2019002953A1 (en) Anti-pd-l1 antibody and its use.
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
MX2020009864A (en) Anti-cd137 antibodies for combination with anti-pd-1 antibodies.
MX2020009863A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies.
MA41873B2 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules which bind to cd3 and cd20, and uses thereof
EA202091984A1 (en) ZETAKIN DIRECTED T-CELL IMMUNOTHERAPY TARGETING THE IL-13 ALPHA 2 RECEPTOR
MA39751B1 (en) Antibody compositions for the treatment of tumors
FR3077574B1 (en) ANTIBODIES DIRECTED AGAINST ENDOTHELIN RECEPTOR SUBTYPE A AND THEIR USES.
MA42523B1 (en) Anti-psma antibodies, bispecific antigen-binding molecules which bind psma and cd3 and uses thereof
MX2023009434A (en) Antibodies against cd112r and uses thereof.